Stockreport

Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 [Seeking Alpha]

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF Pemvidutide's dual GLP-1/glucagon mechanism targets both metabolic and liver endpoints, with ongoing trials in MASH, obesity, and alcohol use disorder. ALT's $285M pr [Read more]